Immunovant Inc. IMVT
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Headquartered in Durham, North Carolina and founded in 2018, the company specializes in immunology and leverages anti-FcRn (neonatal Fc receptor) technology to modulate immunoglobulin G (IgG) levels in…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees315
TickerIMVT
Statistics
Market Cap$7.07B
Revenue (TTM)—
Net Income-$505.6M
Net Margin—
EPS$-2.77
P/E—
P/S—
P/B7.51
EV/EBITDA-10.49
ROE-64.8%
Dividend Yield—
Price$34.66
Data: Twelve Data · Revenue = mcap / P/S